Save time and get answers to complex questions with AI chat
Patent expiration eu dabrafenib?Does lipitor's use influence blood pressure medication type?Is januvia still on the market?Prolia and osteonecrosis?When does guselkumab patent expire?
See the DrugPatentWatch profile for spravato
Spravato is administered as a nasal spray in a medical setting under supervision. Patients take it by using a device that delivers the medication through the nose. After each dose, patients are monitored in the clinic for a period of time as directed by their healthcare provider and the product’s prescribing information.
Patients administer Spravato themselves using the provided nasal-spray device while seated and under observation by healthcare staff. The dose is given in a controlled, step-by-step way so the medication is delivered intranasally (into the nose) rather than by injection or inhalation.
No. Spravato is intended to be given under supervision in a healthcare setting because administration requires monitoring after dosing.
After Spravato is administered, patients remain at the facility so clinicians can monitor for effects and any adverse reactions, consistent with the supervised administration requirement.
Spravato is prescribed based on the specific indication and treatment plan, with dosing frequency determined by the clinician. The number of devices and total dose per session depends on the prescribed regimen.
Other Questions About Spravato :